Real-World Effectiveness of Racotumomab as Maintenance Therapy in Advanced Non-Small Cell Lung Cancer Patients
Authors:
- Sailyn Alfonso AlemánSASailyn Alfonso Alemán
- Haslen Cáceres LaverniaHLHaslen Cáceres Lavernia
- Kirenia Camacho SosaKSKirenia Camacho Sosa
- Soraida C. Acosta BrooksSBSoraida C. Acosta Brooks
- Orestes Santos MoralesOMOrestes Santos Morales
- Carmen E. Viada GonzálezCGCarmen E. Viada González
- Meylán Cepeda PortalesMPMeylán Cepeda Portales
- Mayelín Troche ConcepciónMCMayelín Troche Concepción
- Loipa Medel PérezLPLoipa Medel Pérez
- Leticia Cabrera BenítezLBLeticia Cabrera Benítez
- Milagros C. Domecq SalmónMSMilagros C. Domecq Salmón
- Daymys Estévez IglesiasDIDaymys Estévez Iglesias
Open Access
Abstract
Background: Advanced non-small cell lung cancer (NSCLC) has limited curative options and poor survival. Racotumomab, an anti-idiotype monoclonal antibody vaccine targeting tumor gangliosides, has shown efficacy in clinical trials. This study evaluated its real-world effectiveness as maintenance therapy following first-line chemotherapy. Materials and Methods: A multi-center observational study was conducted on 162 patients with advanced NSCLC who received racotumomab from 2012 to 2024. Effectiveness was evaluated in the intention-to-treat (ITT) cohort. Overall survival (OS) was estimated, with subgroup analyses conducted according to clinical and demographic factors. Results: The median OS was 14.9 months (95% CI: 11.7–18.1), and the 5-year survival rate reached 20%. Patients diagnosed with stage III disease, those with better Eastern Cooperative Oncology Group (ECOG) performance status, and individuals younger than 65 years experienced significantly longer survival. Racotumomab demonstrated a favorable hazard ratio compared to historical controls (HR 0.44 vs. supportive care; HR 0.55 vs. docetaxel). Conclusions: In the era of immune checkpoint inhibitors, these real-world results indicate a promising role for racotumomab in the maintenance setting for advanced NSCLC. These findings provide a strong rationale for further investigation of racotumomab in the context of modern immunotherapy, particularly in combination trials with other immunomodulatory antibodies, along with the validation of clinical and biologic predictive biomarkers.Keywords
Funding Information
- Center of Molecular Immunology
- Cuban Ministry of Health
This publication has 49 references indexed in Scilit:
- Use of cancer vaccine after immunotherapy failure: a promising strategy for advanced NSCLC patients with secondary resistance to checkpoint inhibitorsAnnals of Oncology, 2023
- Associations of tissue tumor mutational burden and mutational status with clinical outcomes in KEYNOTE-042: pembrolizumab versus chemotherapy for advanced PD-L1-positive NSCLCAnnals of Oncology, 2023
- Non‐small cell lung cancer in ChinaCancer Communications, 2022
- Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancerCancer Cell, 2022
- Association of Stage Shift and Population Mortality Among Patients With Non–Small Cell Lung CancerJAMA Network Open, 2021
- Therapeutic vaccines for advanced non-small cell lung cancerCochrane Database of Systematic Reviews, 2019
- Objective assessment of WHO/ECOG performance statusSupportive Care in Cancer, 2019
- Evaluating the Use of Nonrandomized Real‐World Data Analyses for Regulatory Decision MakingClinical Pharmacology & Therapeutics, 2019
- Immunosenescence and cancerBiogerontology, 2017
- Karnofsky and ECOG performance status scoring in lung cancer: A prospective, longitudinal study of 536 patients from a single institutionEuropean Journal of Cancer, 1996